cytarabine
PolandDrugs containing this active substance
-
The medicinal product is used in the treatment of neoplastic diseases, such as acute myeloid and lymphoblastic leukemias, leukemic infiltrates in the central nervous system, and non-Hodgkin lymphomas. It may also be used in treatment-resistant therapies or in the case of blast crisis in chronic myeloid leukemia.
Form: solution for injection
Active substance Dosage cytarabine 20 mg/1 ml ATC: L01BC01
Manufacturer: Ebewe Pharma Ges.m.b.H Nfg. KG Fareva Unterach GmbH
-
The drug is used in the treatment of neoplastic diseases, such as acute leukemias (myeloid and lymphoblastic), leukemic infiltrates in the central nervous system, and non-Hodgkin lymphomas. In high doses, it is also used in cases of treatment-resistant lymphomas or leukemias and in blast crisis in chronic myeloid leukemia.
Form: solution for infusion
Active substance Dosage cytarabine 50,000 mg/ml ATC: L01BC01
Manufacturer: Ebewe Pharma Ges.m.b.H Nfg. KG Fareva Unterach GmbH
-
The medicine is used in adults and children for the treatment of acute leukemias (blood cancers) and for the prevention and treatment of disease involving the central nervous system (leukemia with meningeal involvement).
Form: solution for injection for infusion
Active substance Dosage cytarabine 20 mg/ml ATC: L01BC01
Manufacturer: Accord Healthcare Polska Ltd. Laboratori Fundació Dau
-
The medicine is used in adults and children for the treatment of acute leukemias (blood cancer). It helps to induce and maintain remission, which is a period when disease symptoms subside and blood cell counts return to normal.
Form: solution for injection for infusion
Active substance Dosage cytarabine 100 mg/ml ATC: L01BC01
Manufacturer: Fresenius Kabi Deutschland GmbH
-
CYTOSAR is used in the treatment of acute myeloid leukemia in adults and children, acute lymphoblastic leukemia, and chronic myeloid leukemia. It may be used alone or in combination with other anticancer drugs.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage cytarabine 100 mg ATC: L01BC01
Manufacturer: Actavis Italia s.r.l.
-
CYTOSAR is an anticancer medicine used in the treatment of acute myeloid leukemia in adults and children, acute lymphoblastic leukemia, and chronic myeloid leukemia. It may be administered alone or in combination with other anticancer medicines.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage cytarabine 500 mg ATC: L01BC01
Manufacturer: Actavis Italy S.p.A.
-
CYTOSAR is an anticancer medicine used in the treatment of acute myeloid leukemia in adults and children, acute lymphoblastic leukemia, and chronic myeloid leukemia. It may be used alone or in combination with other anticancer medicines.
Form: powder for preparation of injection solution
Active substance Dosage cytarabine 1 g ATC: L01BC01
Manufacturer: Actavis Italia s.r.l.
-
The medicinal product is used to treat acute myeloid leukaemia in adults and children, as well as to treat acute lymphoblastic leukaemia and chronic myeloid leukaemia. It may also be used to treat leukaemia with central nervous system involvement.
Form: solution for injection for infusion
Active substance Dosage cytarabine 20 mg/ml ATC: L01BC01
Manufacturer: Pfizer Service Company BV
-
The medicine is used for the treatment of acute myeloid leukemia in adults and children, acute lymphoblastic leukemia, and chronic myeloid leukemia. It may be used alone or in combination with other anticancer drugs.
Form: solution for injection for infusion
Active substance Dosage cytarabine 100 mg/ml ATC: L01BC01
Manufacturer: Pfizer Service Company BV